Tag: Phase II HEART

Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor

Coronary/Structural Heart by 0 comments

This randomized, placebo-controlled Phase II clinical study with TOTUM•070 achieved its objective of reducing LDL cholesterol (primary endpoint) and confirmed the very good tolerance of this active substance. As early as 3 months of supplementation, the results showed a significant […]

Continue Reading →